Falk Gastro Info 3/2016

Video

Video course abdominal ultrasound

Examination of abdominal vessels

Superior mesenteric artery, colour Doppler imaging

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

© 2015 Falk Foundation e.V., Freiburg. All rights reserved.

 

Please switch on your loudspeakers!

 

Link to Falk Mediacenter

 

Latest research in brief:

 

Bowel

Text:

Hawkey CJ et al, JAMA. 2015;314(23):2524–34

Autologous hematopoietic stem cell transplantation for Crohn’s disease: no statistically significant improvement in sustained remission as compared to standard therapy.

Link to text

 

Text:

Lembo AJ et al, N Engl J Med. 2016;374(3):242–53

Irritable bowel syndrome with diarrhea: Eluxadoline, a new oral agent with mixed opioid effects, results in symptom reduction over 6 months.

Link to text

 

Text:

Carbonnel F et al, Gastroenterology. 2016;150(2):380–8.e4

Ulcerative colitis: Methotrexate is not superior to placebo for inducing steroid-free remission.

Link to text

 

Liver Biliary Tracts

Text:

Feld JJ et al, N Engl J Med. 2015;373(27):2599–607

Hepatitis C: he once-daily fixed-dose combination tablet sofosbuvir-velpatasvir given for 12 weeks leads to viral clearance in approx. 99% of patients with hepatitis C genotype 1, 2, 4, 5, or 6 (Feld et al.). Even in treatment-experienced patients with genotype 3 and compensated cirrhosis, this regimen leads to viral clearance in 89% of cases (Foster et al.).

Link to text

 

Text:

Armstrong MJ et al, Lancet. 2016;387(10019):679–90

Non-alcoholic steatohepatitis (NASH): In a small clinical trial, 48 weeks of liraglutide treatment led to resolution of NASH on histology in approx. 40% of patients and prevented progression of fibrosis in most patients.

Link to text

 

Text:

Trivedi PJ et al, Gut. 2016;65(2):321–9

Primary biliary cholangitis (PBC): The risk for the development of a hepatocellular carcinoma (HCC) is most significantly associated with biochemical non-response to treatment with ursodeoxycholic acid.

Link to text

 

Oesophagus Stomach Duodenum

Text:

Liou JM et al, Aliment Pharmacol Ther. 2016;43(4):470–81

Helicobacter pylori infection: Sequential therapy for 14 days, but not 10 days, is slightly more effective than 14-day triple therapy as first-line treatment.

Link to text

 

Text:

Miehlke S et al, Gut. 2016;65(3):390–9

Eosinophilic esophagitis: Budesonide as effervescent tablet or viscous suspension is highly effective and safe for short-term treatment of EoE.

Link to text

 

Text:

Ashida K et al, Aliment Pharmacol Ther. 2016;43(2):240–51

Novel therapy for acid-related diseases: Vonoprazan, a novel potassium-competitive acid inhibitor, is non-inferior to lansoprazole in the healing of erosive esophagitis.

Link to text

 

Pancreas

Text:

Koutroumpakis E et al, Am J Gastroenterol. 2015;110(12):1707–16

Acute pancreatitis: Admission hematocrit ≥ 44% and rise of blood urea nitrogen at 24 h may be optimal tools to predict persistent organ failure and pancreatic necrosis.

Link to text

 

International Symposia and Workshops

Symposium 201

Gut-Liver Interactions: From IBD to NASH

March 11 – 12, 2016, Innsbruck, Austria

Congress Innsbruck, Rennweg 3, 6020 Innsbruck, Austria

Program

 

Registration

 

Online registration

 

Symposium 202

Evolving Therapies in Clinical Practice in IBD

April 29 – 30, 2016, Prague, Czech Republic

Hilton Prague, Pobrezni 1, 18600 Prague 08, Czech Republic

Program

 

Registration

 

Online registration

 

Symposium 203

XXIV International Bile Acid Meeting:

Bile Acids in Health and Disease

June 17 – 18, 2016, Düsseldorf, Germany

Hilton Düsseldorf, Georg-Glock-Str. 20, 40474 Düsseldorf, Germany

Program

 

Registration

 

Online registration

Current Falk literature:

Budenofalk® in Daily Practice

A Topical Steroid for Chronic Bowel and Liver Diseases

(29 pages)

Bu8e

Picture:

http://newsletter.drfalkpharma.de/FGI_3-16/Bu8e_6-2-16.jpg

PDF download